Table 1.
Patient demographics
| Total number of patients | 53 |
| Age, median (range) | 61 (20–85) |
| Sex, n (%) | |
| Male | 31 (58) |
| Female | 22 (42) |
| BRAF status, n (%) | |
| Positive | 25 (47) |
| Negative | 22 (42) |
| Unknown | 5 (9) |
| Brain metastases present at initial diagnosis of metastatic melanoma, n (%) | 22 (42) |
| Brain metastases symptomatic, n (%) | 41 (77) |
| Number of brain metastases, n (%) | |
| 1 | 15 (28) |
| 2–3 | 10 (19) |
| >3 | 28 (53) |
| KPS, n (%) | |
| 90–100 | 24 (45) |
| 70–80 | 21 (40) |
| <70 | 8 (15) |
| msGPA score, n (%) | |
| 0–1 | 21 (40) |
| 2 | 12 (23) |
| 3 | 6 (11) |
| 4 | 14 (26) |
| Extra cranial disease presence, n (%) | 42 (79) |
| Treatment for brain metastases, n (%) | |
| Total Neurosurgery | 9 (17) |
| Neurosurgery alone | 3 (6) |
| Total SRS | 8 (15) |
| SRS alone | 3 (6) |
| Total WBRT | 23 (43) |
| WBRT alone | 17 (32) |
| Total Immunotherapy | 9 (17) |
| Immunotherapy alone | 2 (4) |
| Total Targeted BRAF inhibitor | 14 (26) |
| Targeted BRAF inhibitor alone | 8 (15) |
| Combination therapy | 15 (28) |
| Neurosurgery + WBRT | 2 (4) |
| Neurosurgery + targeted BRAF inhibitor | 4 (8) |
| Neurosurgery + SRS + immunotherapy | 2 (4) |
| SRS + immunotherapy | 3 (6) |
| WBRT + targeted BRAF inhibitor | 2 (4) |
| WBRT + immunotherapy | 2 (4) |
| Best supportive care | 5 (9) |